Systemic and Local Interleukin-17 and Linked Cytokines Associated with Sjögren’s Syndrome Immunopathogenesis

Voulgarelis, 1999, Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's Syndrome, Arthritis Rheum, 42, 1765, 10.1002/1529-0131(199908)42:8<1765::AID-ANR28>3.0.CO;2-V

Katsifis, 2007, T lymphocytes in Sjögren's syndrome: contributors to and regulators of pathophysiology, Clin Rev Allergy Immunol, 32, 252, 10.1007/s12016-007-8011-8

Manoussakis, 2007, Arthritis Rheum, 56, 3977, 10.1002/art.23073

Boniface, 2008, From interleukin-23 to T-helper 17 cells: human T-helper cell differentiation revisited, Immunol Rev, 226, 132, 10.1111/j.1600-065X.2008.00714.x

Sankar, 2004, Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial, Arthritis Rheum, 50, 2240, 10.1002/art.20299

Moutsopoulos, 2008, Lack of efficacy of etanercept in Sjögren syndrome correlates with failed suppression of tumour necrosis factor α and systemic immune activation, Ann Rheum Dis, 67, 1437, 10.1136/ard.2007.077891

Mariette, 2004, Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS), Arthritis Rheum, 50, 1270, 10.1002/art.20146

Moutsopoulos, 2006, Immunological consequences of thalidomide treatment in Sjögren's syndrome, Ann Rheum Dis, 65, 112, 10.1136/ard.2005.038406

Wahl, 2007, Transforming growth factor-β: innately bipolar, Curr Opin Immunol, 19, 55, 10.1016/j.coi.2006.11.008

Mangan, 2006, Transforming growth factor-β induces development of the TH17 lineage, Nature, 441, 231, 10.1038/nature04754

Veldhoen, 2006, TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells, Immunity, 24, 179, 10.1016/j.immuni.2006.01.001

Bettelli, 2006, Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells, Nature, 441, 235, 10.1038/nature04753

Manel, 2008, The differentiation of human TH-17 cells requires transforming growth factor-β and induction of the nuclear receptor RORγt, Nat Immunol, 9, 641, 10.1038/ni.1610

Volpe, 2008, A critical function for transforming growth factor-β, interleukin 23 and proinflammatory cytokines in driving and modulating human TH-17 responses, Nat Immunol, 9, 650, 10.1038/ni.1613

Yang, 2008, IL-21 and TGF-β are required for differentiation of human TH17 cells, Nature, 454, 350, 10.1038/nature07021

Chen, 2003, Conversion of peripheral CD4+CD25-naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3, J Exp Med, 198, 1875, 10.1084/jem.20030152

Mavragani, 2007, Augmented interferon-α pathway activation in patients with Sjögren's syndrome treated with etanercept, Arthritis Rheum, 56, 3995, 10.1002/art.23062

Vitali, 2002, Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group, Ann Rheum Dis, 61, 554, 10.1136/ard.61.6.554

Daniels, 1994, Association of patterns of labial salivary gland inflammation with keratoconjunctivitis sicca: analysis of 618 patients with suspected Sjögren's syndrome, Arthritis Rheum, 37, 869, 10.1002/art.1780370615

Tarpley, 1974, Minor salivary gland involvement in Sjögren's syndrome, Oral Surg Oral Med Oral Pathol, 37, 64, 10.1016/0030-4220(74)90160-1

Sakai, 2008, Identification of IL-18 and Th17 cells in salivary glands of patients with Sjögren's syndrome, and amplification of IL-17-mediated secretion of inflammatory cytokines from salivary gland cells by IL-18, J Immunol, 181, 2898, 10.4049/jimmunol.181.4.2898

Nguyen, 2008, Salivary gland tissue expression of interleukin-23 and interleukin-17 in Sjögren's syndrome: findings in humans and mice, Arthritis Rheum, 58, 734, 10.1002/art.23214

Lee, 2009, Late developmental plasticity in the T helper 17 lineage, Immunity, 30, 92, 10.1016/j.immuni.2008.11.005

Christodoulou, 2008, Foxp3+ T-regulatory cells in Sjögren's syndrome: correlation with the grade of the autoimmune lesion and certain adverse prognostic factors, Am J Pathol, 173, 1389, 10.2353/ajpath.2008.080246

Yamazaki, 2008, CCR6 regulates the migration of inflammatory and regulatory T cells, J Immunol, 181, 8391, 10.4049/jimmunol.181.12.8391

Ivanov, 2006, The orphan nuclear receptor RORγt directs the differentiation program of proinflammatory IL-17+ T helper cells, Cell, 126, 1121, 10.1016/j.cell.2006.07.035

Yang, 2008, T helper 17 lineage differentiation is programmed by orphan nuclear receptors RORα and RORγ, Immunity, 28, 29, 10.1016/j.immuni.2007.11.016

Fox, 2005, Sjögren's syndrome, Lancet, 366, 321, 10.1016/S0140-6736(05)66990-5

Jovanovic, 1998, IL-17 stimulates the production and expression of proinflammatory cytokines. IL-β and TNF-α, by human macrophages, J Immunol, 160, 3513, 10.4049/jimmunol.160.7.3513

Moseley, 2003, Interleukin-17 family and IL-17 receptors, Cytokine Growth Factor Rev, 14, 155, 10.1016/S1359-6101(03)00002-9

Kolls, 2004, Interleukin-17 family members and inflammation, Immunity, 21, 467, 10.1016/j.immuni.2004.08.018

Ferraccioli, 1997, Cytokine expression in the salivary glands of Sjögren's syndrome patients in relation to tissue infiltration and lymphoepithelial lesions, Arthritis Rheum, 40, 987, 10.1002/art.1780400537

Isaksen, 2008, Anti-CD20 treatment in primary Sjögren's syndrome, Scand J Immunol, 68, 554, 10.1111/j.1365-3083.2008.02185.x

Mitsias, 2002, The Th1/Th2 cytokine balance changes with the progress of the immunopathological lesion of Sjögren's syndrome, Clin Exp Immunol, 128, 562, 10.1046/j.1365-2249.2002.01869.x

Fox, 1994, Cytokine mRNA expression in salivary gland biopsies of Sjögren's syndrome, J Immunol, 152, 5532, 10.4049/jimmunol.152.11.5532

Ohyama, 1996, Cytokine messenger RNA expression in the labial salivary glands of patients with Sjögren's syndrome, Arthritis Rheum, 39, 1376, 10.1002/art.1780390816

McGeachy, 2007, TGF-β and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain TH-17 cell-mediated pathology, Nat Immunol, 8, 1390, 10.1038/ni1539

Annunziato, 2007, Phenotypic and functional features of human Th17 cells, J Exp Med, 204, 1849, 10.1084/jem.20070663

Gottenberg, 2005, CD4 CD25high regulatory T cells are not impaired in patients with primary Sjögren's syndrome, J Autoimmun, 24, 235, 10.1016/j.jaut.2005.01.015

Dejaco, 2006, Imbalance of regulatory T cells in human autoimmune diseases, Immunology, 117, 289, 10.1111/j.1365-2567.2005.02317.x

Laurence, 2007, Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation, Immunity, 26, 371, 10.1016/j.immuni.2007.02.009

Mucida, 2007, Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid, Science, 317, 256, 10.1126/science.1145697

Zhou, 2008, TGF-β-induced Foxp3 inhibits TH17 cell differentiation by antagonizing RORγt function, Nature, 453, 236, 10.1038/nature06878

Spachidou, 2007, Expression of functional Toll-like receptors by salivary gland epithelial cells: increased mRNA expression in cells derived from patients with primary Sjögren's syndrome, Clin Exp Immunol, 147, 497, 10.1111/j.1365-2249.2006.03311.x

Pasare, 2003, Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells, Science, 299, 1033, 10.1126/science.1078231

Kubo, 2004, Regulatory T cell suppression and anergy are differentially regulated by proinflammatory cytokines produced by TLR-activated dendritic cells, J Immunol, 173, 7249, 10.4049/jimmunol.173.12.7249

Woo, 2005, Arthritis Res Ther, 7, R1281, 10.1186/ar1826

Maini, 2006, Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate, Arthritis Rheum, 54, 2817, 10.1002/art.22033

Krueger, 2007, A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis, N Engl J Med, 356, 580, 10.1056/NEJMoa062382

Mannon, 2004, Anti-interleukin-12 antibody for active Crohn's disease, N Engl J Med, 351, 2069, 10.1056/NEJMoa033402